GPR55 Antibody, FITC conjugated

1. GPR55 is involved in the migratory behavior of human breast cancer cells. PMID: 29188802
2. Inhibition of GPR55 activity produces antitumor effects via attenuation of the MEK/ERK and PI3K-AKT pathways leading to a reduction in the expression and function of MDR proteins. PMID: 27423937
3. our data suggest that GPR55 and CB1 play differential roles in colon carcinogenesis where the former seems to act as oncogene and the latter as tumor suppressor. PMID: 28875496
4. GPR55 was highly expressed by beta-cells of both humans and mice. It was also present in a small proportion of mouse islet alpha-cells and in the majority of human islet alpha-cells, but it was absent or at very low levels in delta-cells of both species. GPR55 was preferentially expressed in the endocrine pancreas, with only faint immunoreactivity in the exocrine pancreas in mice and humans. PMID: 27561953
5. We observed a significantly higher expression of GPR55 mRNA in Crohn's disease (CD) patients compared to ulcerative colitis (UC) and controls. CD patients manifested higher GPR55 mRNA expression in inflamed compared with non-inflamed colonic tissues. In contrast, the analysis of GPR55 mRNA expression in UC patients revealed no statistically significant differences between inflamed and non-inflamed colonic tissue. PMID: 28272905
6. Crucial amino acid residues involved in agonist signaling at the GPR55 receptor have been identified. PMID: 28005346
7. The signalling pathways activated by lysophosphatidylinositol through its receptor GPR55 play a pivotal role in different cancer. [review] PMID: 26588872
8. GPR55 is involved in the migratory behaviour of colon carcinoma cells. PMID: 26436760
9. Inhibiting the pro-angiogenic L-alpha-lysophosphatidylinositol /GPR55 pathway appears a promising target against angiogenesis in ovarian carcinoma PMID: 25989290
10. GPR55 is expressed in placenta,located solely at the placental endothelium; L-alpha-lysophosphatidylinositol (LPI), the endogenous ligand of GPR55, increases migratory activity of venous but not arterial placental endothelial cells suggesting a role of LPI-GPR55 axis in placental venous endothelium function PMID: 25869640
11. GPR55 could play deleterious role in ox-LDL-induced foam cells and could be a novel pharmacological target to manage atherosclerosis and other related cardiovascular diseases. PMID: 25970609
12. GPR55 was a direct target gene of miR-675-5p. PMID: 25889562
13. proinflammatory role in innate immunity PMID: 25344934
14. expression of CB1 and GPR55 in proximal tubules is altered in response to elevated levels of glucose and albumin PMID: 25545857
15. This review summarizes our current knowledge of expression and function of GPR55 in tissues involved in metabolic regulation and the signaling cascades through which GPR55 is reported to act. PMID: 24972076
16. Heteromerization of GPR55 and cannabinoid CB2 receptors modulates signalling PMID: 25048571
17. Data suggest GPR55 (G-protein coupled receptor 55), ABCC1 (ATP-binding cassette sub-family C), and MPR1/ABCB1 (multidrug resistance protein 1) participate/cooperate in autocrine communication/tumorigenesis involving lysophosphatidylinositol. [REVIEW] PMID: 25233417
18. CB2R and GPR55 form heteromers in cancer cells, these structures possess unique signaling properties, and modulation of these heteromers can modify the antitumoral activity of cannabinoids in vivo PMID: 24942731
19. GPR55 receptors were expressed in urothelial cell lines and interact with CB1 receptors. PMID: 24652077
20. GPR55 antagonists occupies a horizontal binding pocket extending into the extracellular loop region, a central ligand portion that fits vertically in the receptor binding pocket. PMID: 24274581
21. Data (including data from tissue bank samples) suggest that GPR55 is strongly expressed on myenteric neurons of the colon. PMID: 23603203
22. Data suggest that GPR55 is functionally expressed in vascular endothelium/platelets and is involved in regulation of calcium signaling; as suspected, lysophosphatidylinositol is a ligand/agonist for GPR55. PMID: 23639801
23. HIV-infected human cells injected into immunodeficient mice to observe expression levels of CB1R, CB2R and GPR55. PMID: 20549374
24. GPR55 drives skin carcinogenesis and is upregulated in human squamous cell carcinomas. PMID: 22751111
25. This article reviews current data about GPR55 pharmacology and signalling, highlighting its involvement in several pathophysiological conditions. [review] PMID: 23151004
26. This review presents a summary of what is known about the G-protein coupled receptors GPR35 and GPR55 and their potential characterization as lysophospholipid or cannabinoid receptors, respectively--{REVIEW} PMID: 22820167
27. CB1 modulates the signaling properties of the lysophosphatidylinositol receptor GPR55. PMID: 23161546
28. Studies suggest the lysophosphatidylinositol (LPI)/orphan G protein-coupled receptor GPR55 axis plays an important role in different physiological and pathological contexts. PMID: 22285325
29. GASP-1 is a key regulator of the trafficking and, by extension, functional expression of GPR55 PMID: 21718301
30. alpha-lysophosphatidylinositol(LPI)/GPR55 system is positively associated with obesity in humans. PMID: 22179809
31. New blood brothers: the GPR55 and CB2 partnership PMID: 21537344
32. GPR55 limits the tissue-injuring inflammatory responses mediated by CB(2)R, while it synergizes with CB(2)R in recruiting neutrophils to sites of inflammation. PMID: 21467997
33. GPR55 is expressed in human tumours and drives proliferation and its expression correlates with tumour aggressiveness PMID: 21367464
34. The chemical diversity provided by three lead compounds combined with the identification of key GPR55 receptor interaction sites should provide a basis for the design of more efficacious second-generation GPR55 ligands that retain GPR55 selectivity. PMID: 21534610
35. this study demonistrated that low-functioning Val195 allele of GPR55 appears to be a risk factor for anorexia nervosa. PMID: 20506567
36. GPR55 is expressed in several prostate and ovarian cancer cell lines and has a critical role in regulating proliferation and anchorage-independent growth. GPR55 mediates the effects of lysophosphatidylinositol in prostate and ovarian cancer cells. PMID: 20838378
37. GPR55 expression in human tumors from different origins correlates with tumor aggressiveness. Moreover, GPR55 promotes cancer cell proliferation through the overactivation of the extracellular signal-regulated kinase cascade. PMID: 20818416
38. results suggest that GPR55 and its endogenous ligand LPI play essential roles in the homoeostatic responses to stress signals in several mammalian tissues and cells including certain types of immune cells PMID: 20051382
39. These results strongly suggest that GPR55 is a specific and functional receptor for lysophosphatidylinositol. PMID: 17765871
40. The GPR55 is a novel cannabinoid receptor, it binds to and is activated by the cannabinoid ligand CP55940 and couples to Galpha13 and can mediate activation of rhoA, cdc42 and rac1. PMID: 17876302
41. establish GPR55 as a cannabinoid receptor with signaling distinct from CB(1) and CB(2). PMID: 18263732
42. in endothelial cells, two receptors for anandamide were found, which were characterized as cannabinoid 1 receptor & and G-protein-coupled receptor 55; integrin clustering enables anandamide-induced Ca2+ signaling in endothelial cells via GPR55 PMID: 18445684
43. Treatment with lysophosphatidylinositol induces marked GPR55 internalization and stimulates a sustained, oscillatory calcium release pathway, which is dependent on Galpha13 and requires RhoA activation. PMID: 18757503
44. GPR55 is an atypical cannabinoid responder. PMID: 19723626
45. Data reveal a role of GPR55 in bone physiology by regulating osteoclast number and function. PMID: 19805329

Show More

Hide All

HGNC: 4511

OMIM: 604107

KEGG: hsa:9290

STRING: 9606.ENSP00000375893

UniGene: Hs.114545